廣告

Has AstraZeneca scared off the vultures?

AstraZeneca says it has agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial $600 million as it reported weak fourth-quarter earnings. Sonia Legg asks if the drug maker is wise to seek external deals to ensure growth.